N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

Cancer ◽

10.1002/cncr.29327 ◽

2015 ◽

Vol 121 (15) ◽

pp. 2537-2543 ◽

Cited By ~ 20

Author(s):

Nina D. Wagner-Johnston ◽

Jeff A. Sloan ◽

Heshan Liu ◽

Ann E. Kearns ◽

Stephanie L. Hines ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Postmenopausal Women ◽

Controlled Trial ◽

Randomized Controlled ◽

Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials

Current Problems in Cancer ◽

10.1016/j.currproblcancer.2019.100507 ◽

2020 ◽

Vol 44 (2) ◽

pp. 100507

Author(s):

Mei Mei ◽

Zijian Xiang ◽

Jinghua Yang ◽

Ruolan Xiang

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Adjuvant Therapy ◽

Early Stage ◽

Meta Analysis ◽

Controlled Trials ◽

Breast Cancer Patients ◽

Randomized Controlled ◽

Correspondence: “Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial”

Spinal Cord ◽

10.1038/s41393-018-0221-9 ◽

2018 ◽

Vol 56 (12) ◽

pp. 1212-1212

Author(s):

Gary S. Beaupre

Keyword(s):

Spinal Cord ◽

Spinal Cord Injury ◽

Zoledronic Acid ◽

Bone Loss ◽

Controlled Trial ◽

Randomized Controlled ◽

Cord Injury ◽

Correspondence Effect ◽

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

PLoS ONE ◽

10.1371/journal.pone.0143643 ◽

2015 ◽

Vol 10 (12) ◽

pp. e0143643 ◽

Cited By ~ 12

Author(s):

Yoshie Hasegawa ◽

Hirokazu Tanino ◽

Jun Horiguchi ◽

Daishu Miura ◽

Takashi Ishikawa ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Primary Breast Cancer ◽

Controlled Trial ◽

Neoadjuvant Treatment ◽

Randomized Controlled

5201 POSTER The EXpand Study – Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone

European Journal of Cancer ◽

10.1016/s0959-8049(11)71643-4 ◽

2011 ◽

Vol 47 ◽

pp. S390 ◽

Cited By ~ 1

Author(s):

M. Hellrieqel ◽

M. Mueller ◽

T. Reimer ◽

D.T. Baerens ◽

A. von der Assen ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Hormone Receptor Positive ◽

Prevention Of Bone Loss ◽

Extended Adjuvant Therapy ◽

Positive Breast Cancer

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Breast Cancer Research and Treatment ◽

10.1007/s10549-009-0332-2 ◽

2009 ◽

Vol 117 (3) ◽

pp. 603-609 ◽

Cited By ~ 55

Author(s):

Stephanie L. Hines ◽

Betty Mincey ◽

Todor Dentchev ◽

Jeff A. Sloan ◽

Edith A. Perez ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Postmenopausal Women ◽

Abstract PD3-7: Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)

10.1158/0008-5472.sabcs13-pd3-7 ◽

2013 ◽

Cited By ~ 1

Author(s):

D Miura ◽

Y Hasegawa ◽

J Horiguchi ◽

T Ishikawa ◽

M Hayashi ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Primary Breast Cancer ◽

Controlled Trial ◽

Neoadjuvant Treatment ◽

Disease Free Survival ◽

Free Survival ◽

Randomized Controlled ◽

Disease Free

Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)

10.1158/0008-5472.sabcs13-ot1-1-06 ◽

2013 ◽

Cited By ~ 3

Author(s):

CE Geyer ◽

S Loibl ◽

EP Mamounas ◽

M Untch ◽

N Wolmark ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Primary Breast Cancer ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Trial

Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2012.11.002 ◽

2013 ◽

Vol 13 (2) ◽

pp. 99-105 ◽

Cited By ~ 12

Author(s):

Jason R. Westin ◽

Michael A. Thompson ◽

Vince D. Cataldo ◽

Luis E. Fayad ◽

Nathan Fowler ◽

...

Keyword(s):

Zoledronic Acid ◽

Bone Loss ◽

Phase Iii ◽

Primary Therapy ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(10)79468-6 ◽

2010 ◽

Vol 21 (1) ◽

pp. 72-74

Author(s):

C.H. Van Poznak ◽

J.E. Brown

Keyword(s):

Breast Cancer ◽

Bone Loss ◽

Primary Breast Cancer ◽

Premenopausal Women ◽

Phase Iii ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽